Thursday, October 22, 2026 Published by AdvancedCare USA Inc.

TheraNews
Subscribe

Archive summary Clinical & research

Compass Pathways Successfully Achieves Primary Endpoint in Second Phase 3 Trial Evaluating COMP360 Psilocybin for Treatment-Resistant Depression

Summary of reporting by rutlandherald 1 min read Markdown

Compass Pathways Successfully Achieves Primary Endpoint in Second Phase 3 Trial Evaluating COMP360 Psilocybin for Treatment-Resistant Depression

Originally reported by rutlandherald. Read more

Source: https://www.rutlandherald.com/news/business/compass-pathways-successfully-achieves-primary-endpoint-in-second-phase-3-trial-evaluating-comp360-psilocybin-for/article_ead19db9-a312-5ef8-8c71-c465e5379762.html

Newsletter

The weekly digest

Weekly digest of US behavioral health policy and regulation, source-linked and practitioner-edited. Free; unsubscribe in one click.